Needham & Company LLC Reiterates Hold Rating for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a note issued to investors on Friday,Benzinga reports.

A number of other research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Raymond James reissued an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Barclays decreased their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $166.00.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $135.42 on Friday. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market capitalization of $13.71 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. The firm’s fifty day moving average price is $123.99 and its 200 day moving average price is $130.59.

Insider Activity at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $28,000. Innealta Capital LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at approximately $30,000. Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares in the last quarter. Plato Investment Management Ltd increased its stake in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at $63,000. 92.59% of the stock is owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.